求購“Saccharin Sodium” BP2017 和BP2018的藥典標(biāo)準(zhǔn)各一份   [更多]

1.Nihon Yakurigaku Zasshi. 2013 Jul;142(1):39-46. doi: 10.1254/fpj.142.39. Pharmacological and clinical properties of AIMIX combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate. 2.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 3.Clin Ther. 2012 Aug;34(8):1705-19. doi: 10.1016/j.clinthera.2012.06.026. Epub 2012 Jul 30. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 4.Clin Ther. 2012 Aug;34(8):1720-34.e3. doi: 10.1016/j.clinthera.2012.07.001. Epub 2012 Jul 30. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 5.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 6J Cardiol. 2019 Mar 20. pii: S0914-5087(19)30053-X. doi: 10.1016/j.jjcc.2019.03.001. [Epub ahead of print] Arginine vasopressin antagonism in heart failure: Current status and possible new directions. Goldsmith SR1. 7.Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability 8.Expert Rev Neurother. 2017 Jan;17(1):59-75. Epub 2016 Oct 20. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology. Tramutola A1, Arena A1,   [更多]

求DOF 2019年1-3期文獻(xiàn)   [更多]

標(biāo)題：求購克拉霉素緩釋片USP41標(biāo)準(zhǔn) 詳細(xì)要求： 需求名稱：克拉霉素緩釋片標(biāo)準(zhǔn) 具體要求：USP42 要求時間：請在2019年05月15日之前 交稿方式：直接點擊交稿在線交稿就是了，我會每天過來看的，謝謝各位藥智的戰(zhàn)友們   [更多]

① 從任務(wù)主手中獲取指定企業(yè)的年報文件， ② 將年報中的相應(yīng)數(shù)據(jù)填入相應(yīng)表格，年報中沒有的數(shù)據(jù)表格相應(yīng)內(nèi)容不做填寫， ③ 要求仔細(xì)認(rèn)真，熟悉英文或?qū)Ψg工具的熟練使用， ④ 價格215元完成已有的86份年報數(shù)據(jù)提取(≈2.5元/份)（填寫完了審核通過，每個年報要求把所有產(chǎn)品銷售額收集填寫完）， ⑤ 如若審核發(fā)現(xiàn)有填錯，填漏；以每填錯，填漏一個數(shù)據(jù)1元計量扣除賞金。   [更多]

求歐洲藥典關(guān)于B19病毒檢測方法的技術(shù)方法及要求，214頁原文。如有其它各國藥典標(biāo)準(zhǔn)對比則更好。   [更多]

ID：嘻嘻嘻嘿嘿嘿，領(lǐng)取賞金；處理統(tǒng)計之后藥智網(wǎng)未收載的說明書數(shù)量為36條，已收載的說明書條數(shù)為43條，總的賞金=36*5+43*3=309   [更多]

需要地奧司明英國藥典的標(biāo)準(zhǔn)。 BP2017或者BP2018 或者2019都可以。   [更多]

公司需求幾篇藥品文獻(xiàn)資料。臨床應(yīng)用數(shù)據(jù)。具體產(chǎn)品私信我找到一篇50元   [更多]

求購 “Talc”《 JP17(英) 》的藥典標(biāo)準(zhǔn)一份. 需求名稱：“Talc”《 JP17(英) 》 要求時間：請在2019年4月16號之前   [更多]